Showing 671-680 of 1601 results for "".
- Pfizer Announces FDA Acceptance For Review of Supplemental New Drug Application for Oral Xeljanz For Plaque Psoriasishttps://practicaldermatology.com/news/pfizer-announces-fda-acceptance-for-review-of-supplemental-new-drug-application-for-oral-xeljanz-for-plaque-psoriasis/2459011/The FDA accepted for review Pfizer Inc.’s supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) 5mg and 10mg tablets, a Janus kinase (JAK) inhibitor, the first in a new class of oral medicines being investigated for the treatment of adult patients with moderate to sever
- Dermira and UCB Announce Start of Phase 3 Program for Cimzia® (Certolizumab Pegol) in Psoriasishttps://practicaldermatology.com/news/dermira-and-ucb-announce-start-of-phase-3-program-for-cimzia-certolizumab-pegol-in-psoriasis/2459027/Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients (NASDAQ: DERM), and UCB, a global biop
- L'oreal USA Announces Changes In Leadership Within Active Cosmetics Divisionhttps://practicaldermatology.com/news/loreal-usa-announces-changes-in-leadership-within-active-cosmetics-division/2459045/Marc Toulemonde was appointed President of the Active Cosmetics Division of L’Oreal USA. In this role, Mr. Toulemonde will work on the SkinCeuticals, La Roche-Posay, Dermablend, and Vichy brands in the United States. Mr. Toulemonde brings expertise to the role from his m
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- Syneron Candela Announces FDA Clearance of PicoWay Picosecond Laser for Tattoo Removalhttps://practicaldermatology.com/news/20141103-syneron_candela_announces_fda_clearance_of_picoway_picosecond_laser_for_tattoo_removal/2459076/The FDA granted 510(K) clearance to Syneron Candela's PicoWay picosecond device for tattoo removal. PicoWay is a dual wavelength device, with 1064nm and 532nm wavelengths, which utilizes the proprietary PicoWay Technology to generate picosecond pulses for the removal of tattoos. The FDA clearanc
- Nerium International Announces Creation of Scientific Advisory Boardhttps://practicaldermatology.com/news/20141027-nerium_international_announces_creation_of_scientific_advisory_board/2459078/Nerium International established a Scientific Advisory Board, comprised of the following scientists and dermatologists: Dr. Adam Friedman, Dr. Neal Bhatia, Dr. Mira Stotland, Marie Bertrand, Dr. Debra J. Wattenberg, and Dr. Karthik Krishnamurthy. The mission of the
- Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directorshttps://practicaldermatology.com/news/20140923-medimetriks_pharmaceuticals_announces_new_members_elected_to_board_of_directors/2459108/Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of
- EAU THERMALE AVÈNE AND KLORANE WIN AT 18th ANNUAL ALLURE BEST OF BEAUTY AWARDS 2014https://practicaldermatology.com/news/20140922-eau_thermale_avne_and_klorane_win_at_18th_annual_allure_best_of_beauty_awards_2014/2459109/In the category of Big Breakthrough, whichacknowledged only 16 winners, Avène earned top honors for the Avène XeraCalm A.D Lipid-Replenishing collection, newly launched in January of this year. In its third consecutive year of being recognized in the Best of Beauty Awards,
- The ISDS Welcomes the Dermatology Community to Jerusalemhttps://practicaldermatology.com/news/20140917-the_international_society_for_dermatologic_surgery_welcomes_the_dermatology_community_to_jerusalem/2459116/The 35th Annual International Society for Dermatologic Surgery (ISDS) Congress will be held in Jerusalem from October 22-24, 2014. The ISDS will have the newest and latest techniques dermatologic surgery, skin cancer surgery, laser surgery, hair transplantation, varicose veins, lipolysis,
- Trevi Therapeutics Announces the Issuance of Two Patents for Oral Sustained Release Formulation of Nalbuphine ERhttps://practicaldermatology.com/news/20140815-trevi_therapeutics_announces_the_issuance_of_two_patents_for_oral_sustained_release_formulation_of_nalbuphine_er/2459144/Trevi Therapeutics, Inc. received two issued U.S. patents with claims protecting the oral sustained release formulation of nalbuphine. The patent numbers are 8,771,732 and 8,765,175. The Company believes that both of these patents will be Orange Book-li